

(12) PATENT APPLICATION PUBLICATION

(21) Application No.202541066081 A

(19) INDIA

(22) Date of filing of Application :10/07/2025

(43) Publication Date : 26/09/2025

(54) Title of the invention : A METHOD OF USING OXALIPLATIN OR CISPLATIN AS INHIBITOR OF FRUCTOSAMINE-3-KINASE (FN3K) FOR CANCER TREATMENT

(51) International classification :A61P0035000000, G01N0027447000, A61K0033243000, B01D0071340000, A61K0031555000

(86) International Application No :NA

Filing Date :NA

(87) International Publication No : NA

(61) Patent of Addition to Application Number :NA

Filing Date :NA

(62) Divisional to Application Number :NA

Filing Date :NA

(71)Name of Applicant :

1)JSS College of Pharmacy, Mysuru, JSS Academy of Higher Education & Research (Deemed to be university)

Address of Applicant :Sri Shivarathreshwara Nagara, Mysuru, Karnataka, India-570015 Mysore -----

Name of Applicant : NA

Address of Applicant : NA

(72)Name of Inventor :

1)Dr. Narasimha M Beeraka

Address of Applicant :Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru, Karnataka, India Mysore -----

2)Dr. Gurupadayya Bannimath

Address of Applicant :Department of Pharmaceutical Chemistry, JSS College of Pharmacy, Mysuru, Karnataka, India. Mysore -----

(57) Abstract :

A METHOD OF USING OXALIPLATIN OR CISPLATIN AS INHIBITOR OF FRUCTOSAMINE-3-KINASE (FN3K) FOR CANCER TREATMENT ABSTRACT
A method (400) of using oxaliplatin (210) or cisplatin (208) as an inhibitor of fructosamine- 3-kinase (204) for use in cancer treatment is provided. The method (400) includes sampling (402) about 50 µg of proteins from oxaliplatin (5 210) and cisplatin (208) drug-treated lysates of T-47D breast cancer cell lines for Sodium dodecyl sulfatepolyacrylamide gel electrophoresis, separating (404) and transferring of proteins into at least one of PVDF membrane or nitrocellulose membrane (202) followed by blocking (406) at least one of the membrane (202) using 5 % skimmed milk, subjecting (408) 10 at least one of the membrane (202) to primary antibody and subjecting at least one of incubated membrane (202) for further incubation with HRP-linked secondary antibody for about two hours followed by adding (410) enhanced chemiluminescence reagent to at least one of the membrane (202) and observing for banding pattern in chemi-UV tech till the appearance of bands in the western blotting. 15 [FIGS. 4A&4B]

No. of Pages : 30 No. of Claims : 12